{"id":"NCT00779103","sponsor":"Endo Pharmaceuticals","briefTitle":"Histrelin Subcutaneous Implant in Children With Central Precocious Puberty","officialTitle":"Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09","primaryCompletion":"2011-08","completion":"2012-04","firstPosted":"2008-10-24","resultsPosted":"2021-01-08","lastUpdate":"2021-01-08"},"enrollment":36,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Central Precocious Puberty"],"interventions":[{"type":"DRUG","name":"Histrelin Subcutaneous Implant","otherNames":["Supprelin LA","implant therapy","histrelin implant"]}],"arms":[{"label":"Histrelin Subcutaneous Implant (50 mg)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to follow and collect additional medical and developmental information on children after histrelin subcutaneous implant therapy is discontinued.","primaryOutcome":{"measure":"Luteinizing Hormone (LH)","timeFrame":"Baseline - 6 Months Post Last Implant","effectByArm":[{"arm":"Observed Value","deltaMin":0.88,"sd":1.244}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25803268","24295437"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":31},"commonTop":["Implant Site Reaction","Upper Respiratory Tract Infection","Nasopharyngitis","Headache","Pharyngitis Streptococcal"]}}